Fig. 5: Predictive biomarkers in the context of tumour subtypes. | Nature Communications

Fig. 5: Predictive biomarkers in the context of tumour subtypes.

From: The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer

Fig. 5

Overview of interaction biomarkers (FDRint < 0.2) focusing on a mutant and b wild-type tumours when comparing cetuximab and bevacizumab treatment, using hazard ratios including 95% confidence intervals (CI) derived from single Cox regression models fitted on OS. Triangle points and confidence intervals were obtained from the bootstrap-based bias-correction of treatment effects. For the conducted statistical tests, the sample sizes are given in Supplementary Data 3. Here exemplified, Kaplan–Meier plots including 95% CIs, hazard ratios and raw p-values derived by Wald tests from the Cox regression models compare treatments in subgroups for c ARFRP1 amplifications in CMS2 and d, e KRAS mutations in CMS4. Source data for the figure panels are provided as Source Data file.

Back to article page